Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Ixazomib Phase III Trial Discontinued in AL Amyloidosis

June 6th 2019

Ixazomib in combination with dexamethasone did not demonstrate a significant improvement in overall hematologic response compared with standard therapy in patients with relapsed/refractory systemic light-chain amyloidosis, missing one of two primary endpoints in the phase III TOURMALINE-AL1 trial and leading to discontinuation of the study.

Expert Highlights Current State of Severe Aplastic Anemia

June 6th 2019

Carlos Manuel de Castro III, MD, highlights current treatment approaches for severe aplastic anemia and some of the unmet needs that still exist.

FDA Grants Momelotinib Fast Track Designation in Myelofibrosis

June 5th 2019

The FDA has granted momelotinib a fast track designation for use as a treatment of patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor.

Targeted Therapies Advance Treatment in AML, But Toxicity Challenges Remain

June 5th 2019

Harry P. Erba, MD, PhD, provides insight into how to navigate through the targeted therapies available in the treatment of acute myeloid leukemia and discussed the work that lies ahead in this space.

FDA Accepts BLA for Luspatercept in MDS, Grants Priority Review in Beta-Thalassemia

June 5th 2019

The FDA has accepted a biologics license application for the investigational erythroid maturation agent luspatercept for the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndromes-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions, as well as for adult patients with beta-thalassemia-associated anemia who require RBC transfusions.

Dr. Sweetenham on Unanswered Questions With CAR T-Cell Therapy in Pediatric ALL

June 1st 2019

John Sweetenham, MD, associate director for clinical affairs, Harold G. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses unanswered questions with CAR T-cell therapy in pediatric acute lymphoblastic leukemia.

Pipeline Updates Advance Paradigms Across Lymphomas

May 31st 2019

Matthew S. McKinney, MD, discusses exciting treatment advances made in Hodgkin and non-Hodgkin lymphoma, specifically the compelling research in follicular lymphoma and mantle cell lymphoma.

Dr. Runaas on Impactful Targeted Therapies in FLT3-Positive AML

May 31st 2019

Lyndsey Runaas, MD, an assistant professor at the Medical College of Wisconsin, discusses impactful targeted therapies for patients with FLT3-mutant acute myeloid leukemia (AML).

FDA Grants Copanlisib Breakthrough Designation for MZL

May 30th 2019

The FDA has granted copanlisib (Aliqopa) a breakthrough therapy designation for the treatment of adult patients with relapsed marginal zone lymphoma who have received at least 2 prior therapies.

FDA Updates Gilteritinib AML Label With OS Data

May 30th 2019

The FDA approved a supplemental new drug application to update the label for gilteritinib to include final analysis data from the phase III ADMIRAL trial, which demonstrated an improvement in overall survival with the FLT3 inhibitor compared with salvage chemotherapy in adult patients with relapsed/refractory FLT3-mutant acute myeloid leukemia.

FDA Approves Lenalidomide/Rituximab for Indolent Non-Hodgkin Lymphoma

May 28th 2019

The FDA has approved the R2 regimen of lenalidomide plus rituximab for use in patients with previously treated follicular lymphoma and marginal zone lymphoma.

OncLive Honors 15 Trailblazers With Giants of Cancer Care Program

May 28th 2019

Fifteen world-renowned leaders in hematology and oncology whose research has improved and extended the lives of millions of patients make up the 2019 class of Giants of Cancer Care® award winners.

FDA Approves Ruxolitinib for Steroid-Refractory Acute GVHD

May 24th 2019

The FDA has approved ruxolitinib for the treatment of adult and pediatric patients ≥12 years of age with steroid-refractory acute graft-versus-host disease.

FDA Panel Votes Against Quizartinib for AML

May 15th 2019

The FDA’s Oncologic Drugs Advisory Committee voted 8-3 against approving a new drug application for quizartinib for adult patients with relapsed/refractory FLT3-ITD–positive acute myeloid leukemia.

Targeted Therapies Transform Outlook of FLT3- and IDH-Mutant AML

May 8th 2019

Lyndsey Runaas, MD, discusses the newfound outlook for patients with FLT3- and IDH1/2-mutant acute myeloid leukemia given recent regulatory approvals and trial data.

Emerging Agents Spur Optimism in Myeloma

May 7th 2019

Saurabh Chhabra, MD, MS, highlights emerging agents in the field of relapsed/refractory myeloma that have oncologists optimistic for the future.

Ruxolitinib Combos Explored to Address MPN-Associated Symptoms

May 6th 2019

Laura Michaelis, MD, highlights the many ruxolitinib combinations under investigation and provided insight into the role of interferon in myeloproliferative neoplasms.

Large Myeloma Study Aims to Analyze Multiple Regimens

May 6th 2019

Therapy for patients with multiple myeloma encompasses many agents and potential combinations, but truly personalizing care will require knowing how those agents interact for maximum efficacy and incorporating patient preferences for toxicity into the care plan.

Dr. Dhakal on Early Data With BiTEs in Multiple Myeloma

May 3rd 2019

Binod Dhakal, MD, assistant professor, Medical College of Wisconsin, discusses early data with bispecific T-cell engager (BiTE) antibody constructs in multiple myeloma.

Dr. Winer Discusses the FDA Approval of Ivosidenib in AML

May 2nd 2019

Eric Stephen Winer, MD, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the FDA approval of ivosidenib in acute myeloid leukemia (AML).